Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in
treating patients with persistent/chronic Immune Thrombocytopenic Purpura (ITP) over a 5 year
period.